[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596972":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":44,"centralContacts":48,"locations":28,"responsibleParty":55,"collaborators":28,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":28,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":28,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":28,"overallStatus":80,"whyStopped":28,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":28},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"VEN+DAC+Bu2Flu4","EXPERIMENTAL","Venetoclax+Decitabine+Busulfan+Fludarabine",[13,14,15,16],"Drug: Venetoclax (VEN)","Drug: Decitabine (DAC)","Drug: Busulfan (Bu)","Drug: Fludarabine (Flu)",{"label":18,"type":19,"description":20,"interventionNames":21},"Bu2Flu5","ACTIVE_COMPARATOR","Busulfan+Fludarabine",[15,16],[23,29,33,37,41],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Venetoclax (VEN)","Venetoclax (VEN) was administered at 400mg\u002Fday on days -10 to -4.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Decitabine (DAC)","Decitabine (DAC) was administered at 20mg\u002Fm2\u002Fday on days\n\n-10 to -8.",[9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Busulfan (Bu)","Busulfan (Bu) was administered at 3.2 mg\u002Fkg\u002Fday on days\n\n-5 to -4.",[18,9],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Fludarabine (Flu)","Fludarabine (Flu) was administered at 30mg\u002Fm2\u002Fday on days -5 to -2.",[9],{"type":24,"name":38,"description":42,"armGroupLabels":43,"otherNames":28},"Fludarabine (Flu) was administered at 30mg\u002Fm2\u002Fday on days -6 to -2.",[18],[45],{"name":46,"affiliation":5,"role":47},"Qifa Liu","PRINCIPAL_INVESTIGATOR",[49,53],{"name":46,"role":50,"phone":51,"phoneExt":28,"email":52},"CONTACT","+86-020-62787883","liuqifa628@163.com",{"name":46,"role":50,"phone":54,"phoneExt":28,"email":52},"+86-020-61641611",{"type":56,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100596972","phase-2-vendacbu2flu4-vs-bu2flu5-conditioning-regimen-for-elderly-myeloid-malignancies-undergoing-allo-hsct-100596972",false,"NCT07052422","VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT","Venetoclax+Decitabine+Busulfan+Fludarabine (VEN+DAC+Bu2Flu4) vs Busulfan+Fludarabine Conditioning Regimen (Bu2Flu5 ) for Older Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)","Inclusion Criteria:\n\n* 60-75 years\n* Acute myeloid leukaemia in first complete remission or myelodysplastic syndrome\n* Willing to undergo the first allo-HSCT\n* Eastern Cooperative Oncology Group performance status of 0-2\n\nExclusion Criteria:\n\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","ALL","60 Years","75 Years",{"count":68,"type":69},160,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE2","PHASE3","The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).",[76,77,78,79],"Older Patients","Myeloid Malignancies","Conditioning","Hematopoietic Stem Cell Transplantation (HSCT)","NOT_YET_RECRUITING","2025-07-01",{"date":83,"type":84},"2025-07-04","ACTUAL",{"date":86,"type":69},"2025-07-15",{"date":88,"type":69},"2029-12-31",{"name":5,"class":6}]